MedInCell Stock Tests Key Technical Support Despite +77% Yearly Gain
The Montpellier-based biotech stock fell this Monday, April 13, amid a general pullback in European markets. MedInCell traded at 22.80 euros during the session, down 1.81% from last Friday's close. The company, which will publish its annual results on June 16, shows a contrast between a strong annual performance and a less favorable recent quarter.
During the session, MedInCell fell by 1.81% to 22.80 euros, following the CAC 40, which lost 1.01% at 8,176.58 points. The SBF 120 also dropped by 1.01%. Other healthcare sector stocks followed the same trajectory, like Sanofi (-1.46%) and UCB (-0.87%). Over the past week, the stock has declined by 1.3%, while over three months, the correction reached 13.7%. This movement contrasts with the year-on-year performance, which remains strongly positive at +77.57%. The next key event for the company will be the publication of its annual results for the fiscal year 2025-2026, scheduled for June 16, followed by the general meeting on September 10.
Technical Analysis
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical standpoint, MedInCell's share price is currently very close to its 50-day moving average, set at 22.78 euros, which now acts as a pivotal zone. However, the 200-day moving average is at 23.64 euros, above the current price, indicating a slight weakening of the medium-term momentum compared to the long-term trend. The Relative Strength Index (RSI), which measures overbought or oversold conditions of a stock, stands at 57, indicating a neutral zone without extreme signals. As for the Bollinger Bands, the price is positioned in the upper part of the band (77%), between an upper limit at 23.70 euros and a lower limit at 19.74 euros. The nearest resistance threshold is at 24.04 euros, a level that needs to be crossed to trigger an upward acceleration. The major support to watch remains set at 20.24 euros.
We are pleased with the company’s growth and momentum.
Total income €14,1 million; Revenues €11,6 million (+35 %); UZEDY® royalties €4,2 million; Operating result €(6,6) million (improved 13 % year-over-year); Net result €(16 078) thousand; Cash and low-risk financial investments €53,5 million (incl. €49,8 million cash and €3,7 million low-risk investments); Net financial debt €17 629 thousand; NDA for Olanzapine LAI submitted to FDA on December 9, 2025; AbbVie partnership advancing with regulatory package expected in 2026.
Risks mentioned
Foreign exchange risk: weakness of USD vs EUR impacted revenues and generated ~€1 million FX losses
Dependency on partner commercialization (Teva) for UZEDY® royalties and sales forecasts
Regulatory risk: approvals (e.g., Olanzapine LAI) and acceptance for review uncertain
Financial volatility linked to fair value revaluation of EIB BSA warrants (non-cash €6,8 million impact)
Opportunities identified
Olanzapine LAI: NDA submitted and potential launch could be a major growth catalyst
UZEDY®: upward revision of 2025 net sales forecast by Teva (from $160 million to $190-200 million)
AbbVie partnership: first program advancing toward first-in-human trials (regulatory package expected 2026)
Gates Foundation financing: new $3 million envelope to advance mdc-STM malaria program
Expanded geographic approvals (Canada, South Korea) supporting broader commercialization
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
